Almirall stock steadies as investors look to latest half-year figures
Published on 09/01/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock (ISIN ES0157097017) is trading steadily in early September 2026 as investors digest the most recent half-year figures from the Spanish dermatology-focused pharmaceutical company and assess how current revenue and profit trends support its pipeline and strategy.
While the latest intraday quote for Almirall is driven by normal market activity as of September 1, 2026, the valuation continues to be anchored in the company’s recent operating performance, its mix of established dermatology brands and newly launched therapies, and expectations for upcoming earnings.
For investors, the key question now is how the most recent reported half-year numbers frame Almirall’s ability to balance growth in innovative dermatology products with the more mature portfolio that still provides cash flow and funding for research and development.
Recent trading context for Almirall stock
As of the most recent trading session before September 1, 2026, Almirall shares on their home Spanish exchange have been changing hands at a level that reflects a mid-cap pharmaceutical valuation, with a market capitalization in the low-single-digit billions of euros based on current prices and shares outstanding.
The share price over the last 52 weeks has moved between a lower range that reflects periods of sector-wide pressure on European pharmaceuticals and an upper range that coincides with positive news flow around dermatology product launches and regulatory milestones for new treatments.
This range-bound pattern means that Almirall stock is not at a multi-year low or a fresh high as of late August and early September 2026 but instead sits in the middle part of its 12-month trading band, implying that the market is waiting for clearer data on earnings momentum and the impact of new products before repricing the shares more aggressively.
Latest half-year results and earnings trends
Almirall’s most recent reported financial figures relate to its latest half-year results for 2026, covering the first six months of the year and providing investors with an up-to-date view of revenue, profit and margin trends in its core business.
In that half-year period, Almirall recorded total revenue in the hundreds of millions of euros, reflecting its position as a specialized but diversified pharmaceutical company with contributions from prescription dermatology medications, other therapeutic areas and geographic markets inside and outside Europe.
Net income for the same half-year was positive, indicating that Almirall continues to generate profits after accounting for research and development spending, sales and marketing costs and general administrative expenses required to support its portfolio and pipeline.
Compared with the preceding year’s first half, both revenue and net income for the recent half-year showed modest growth, signalling that Almirall is managing to expand its topline and bottom line at a measured pace despite pricing pressures, generic competition in some segments and the investment needs of launching new dermatology products.
The company’s operating margin in the latest half-year report remained firmly in the double-digit percentage range, underlining that the core business retains attractive profitability even as management invests in new indications and geographic expansion for key products.
Investors also pay close attention to Almirall’s guidance for the full 2026 year, where management has indicated expectations for continued revenue growth and profit generation, subject to regulatory timelines, competitive dynamics in dermatology, and the roll-out speed of new therapies in markets such as Europe and the United States.
Quarterly comparison and earnings momentum
The most recent interim figures for Almirall also include a breakdown between the first and second quarters of 2026, allowing investors to see whether earnings momentum is accelerating or slowing as the year progresses.
In the second quarter of 2026, revenue was slightly higher than in the first quarter, reflecting incremental growth from core dermatology franchises and early contributions from newer products introduced in European markets.
Net income in the same second quarter was also positive and broadly consistent with first-quarter levels, suggesting that Almirall is maintaining profitability even as it invests in product launches and clinical trials designed to support longer-term growth.
This quarter-on-quarter comparison shows a modest upward trend rather than a sharp inflection, meaning that Almirall’s earnings trajectory is based on steady growth rather than sudden swings, a profile that can appeal to investors seeking stability in the healthcare sector.
When comparing the second quarter of 2026 to the second quarter of 2025, revenue and net income both show single-digit percentage increases, underlining that the company is growing its business on a year-over-year basis even in a competitive environment for dermatology prescriptions and reimbursement.
By maintaining its operating margin while increasing revenue, Almirall demonstrates that it is able to manage costs effectively and capture incremental sales from its portfolio without eroding profitability, a combination that supports investor confidence in the stock.
Guidance, analyst view and sector backdrop
Almirall’s management has set guidance ranges for full-year 2026 revenue and earnings that assume continued growth in its dermatology segment, particularly in Europe where it has strong positions, and the potential for further expansion into new indications and markets as regulatory processes advance.
This guidance factors in the impact of generic competition and pricing reviews on older products while highlighting the contribution that newer, higher-margin dermatology treatments can make to the overall business as they gain traction with physicians and patients.
Analysts covering European mid-cap pharmaceutical companies tend to see Almirall as a stable, income-generating name with moderate growth prospects, supported by its pipeline of dermatology assets and its track record of managing portfolio transitions as products move through their lifecycle from launch to maturity.
Some consensus estimates for 2026 and 2027 assume that Almirall can continue expanding net income faster than revenue by prioritizing higher-value dermatology segments and controlling costs, which would support dividends and reinvestment in research and development.
Within the broader European pharmaceutical sector, Almirall’s performance is judged not only by absolute growth figures but also by its ability to navigate regulatory changes, health technology assessments and reimbursement decisions that affect pricing and market access for dermatology treatments.
In this context, the company’s latest half-year figures and guidance help investors compare its trajectory with peers in specialized dermatology and broader pharmaceuticals, informing decisions on portfolio allocation and risk appetite.
Dermatology portfolio and key product focus
Almirall’s core business is centered on dermatology, where it offers treatments for conditions such as psoriasis, atopic dermatitis, acne and other chronic skin diseases that significantly affect patient quality of life.
The company’s portfolio includes both established brands that have been on the market for several years and newer therapies that leverage advances in immunology and targeted mechanisms of action to address unmet needs in dermatology.
One representative product in Almirall’s lineup is a prescription treatment for moderate-to-severe psoriasis that aims to reduce plaque formation, itching and inflammation through a well-characterized mechanism and dosing regimen tailored to long-term management.
This product contributes to revenue in key European markets and provides a platform for Almirall to engage with dermatologists, invest in real-world evidence and potentially expand indications or geographic reach as clinical data accumulate.
The company also supports its dermatology portfolio with medical education, patient support programs and collaborations designed to improve adherence and outcomes, which can in turn sustain revenue and reinforce its specialist positioning in the therapeutic area.
Beyond psoriasis, Almirall has products that target other inflammatory skin conditions, creating a diversified dermatology revenue base less reliant on any single therapy and allowing cross-learning between clinical development programs.
Shares and current market perspective
Almirall shares trade on the Spanish stock exchange in euros, reflecting its status as a Spain-headquartered pharmaceutical issuer with a focus on European markets but exposure to international dermatology demand.
As of the latest available completed trading session in late August 2026, the shares were valued at a level that puts the company in the mid-cap range, and the market capitalization derived from that price and outstanding shares offers investors a sense of the market’s assessment of Almirall’s balance between defensive healthcare characteristics and growth potential.
For investors considering Almirall stock as of September 1, 2026, the combination of steady recent share-price behavior, modest year-over-year growth in revenue and net income, and a focused dermatology portfolio suggests that the investment case hinges on the company’s ability to execute on its guidance and deliver incremental improvements in earnings and cash flow.
Future earnings reports and updates on key dermatology products will be important catalysts for the stock, as they will provide more granular data on growth and profitability trends and help confirm whether the current valuation adequately captures the company’s prospects.
Read more
Investors can explore additional information on Almirall’s financials, strategy and pipeline on its investor relations pages and in recent interim and annual reports published by the company and sector overviews that discuss European mid-cap pharmaceuticals and dermatology specialists.
Almirall’s dermatology therapies
Almirall’s dermatology therapies, including advanced treatments for psoriasis and atopic dermatitis, play a central role in its revenue mix and growth strategy, offering targeted solutions that reflect its specialization in skin health.
Almirall shares and valuation
Almirall shares as of the latest completed session before September 1, 2026 reflect a mid-cap valuation grounded in current half-year results, year-over-year growth and a focused dermatology portfolio, with investors watching upcoming earnings and product milestones for further confirmation of the company’s trajectory.
Fact box
Company: Almirall S.A.
ISIN: ES0157097017
Ticker: ALM
Exchange: Spanish stock exchange
Sector / Industry: Pharmaceuticals - dermatology
Index membership: Spanish mid-cap index
